Clinical Trials Sponsored by FindCure Biosciences (ZhongShan) Co., Ltd.

Total 302 results

Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers

Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China

Recurrent/Refractory Malignant Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (JUPITER06)

Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

Heterozygous Familial Hypercholesterolemia

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Efficacy and Safety of MW031 in PMO Subjects

Osteoporosis, Postmenopausal

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Advanced Hepatocellular Carcinoma (HCC)

Italy, Poland, Singapore, United States, China, Ukraine
Shanghai Junshi Bioscience Co., Ltd.

Withdrawn

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Primary Condition: Advanced Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection (JUPITER 04)

Hepatocellular Carcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

Bone Metastases

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Treatment-naive Advanced Non-small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Recurrent or Metastatic NPC

China, Taiwan, Singapore
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

Hyperlipemia

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults (MW032)

Bone Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma

Malignant Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..

Hyperlipemia

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects

COVID-19; and High Infection Risk of SARS-CoV-2

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

Hypercholesterolemia

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer

Breast Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors

Lymphoma | Lung Cancer

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Hodgkin Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Limited-stage Small Cell Lung Cancer (LS-SCLC)

China, France, United States, Spain, Taiwan, Korea, Republic of, Turkey, Italy, Netherlands, Georgia, Germany, Belgium, Poland, Romania
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study of 7MW3711 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China
Guangzhou Henovcom Bioscience Co. Ltd.

Recruiting

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension

Parkinson's Disease

United States
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

Advanced Solid Tumors

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections

Skin Infection

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD

Wet Age-related Macular Degeneration

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm

Advanced Malignant Neoplasm

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Clinical Study of JS201 in Patients With Advanced Malignant Tumors

Patients With Advanced Malignant Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

Melanoma | Urothelial Carcinoma | Renal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Locally Advanced or Metastatic Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Non-small Cell Lung Cancer

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Active, not recruiting

Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject

Healthy

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Study Explore JS001+JS002 in Patients With Advanced Cancer

Advanced Cancer

China
Guangzhou Henovcom Bioscience Co. Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

IPF

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment (JS001)

NSCLC

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC

Nasopharyngeal Carcinoma | Head and Neck Squamous Cell Carcinom

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19

COVID-19

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Phase I Study of JS108 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Active, not recruiting

An Evaluation of 9MW1911 Injection in Healthy Subjects

Asthma | Atopic Dermatitis | COPD

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Hyperlipemia

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment (TORCHLIGHT)

Triple-Negative Breast Cancer

China

3

Subscribe